Zydus Lifesciences gets 10 observations from USFDA for Jarod injectable facility

The company will closely work with the USFDA to address and respond to the observations in an expeditious manner

AbbVie's phase 3 Select -GCA study of Upadacitinib showed positive results in patients with giant cell arteritis

Open a printable version of this pageEmail the URL of this page to a friend

Kwality Pharmaceuticals receives approval from INVIMA for Ampoule and Vial product lines

Approval from Colombia's INVIMA will accelerate growth in Colombia, by registering our product and getting regular supplies

Evotech and Variant Bio partner to develop fibrosis treatment

Commercial terms include research funding and milestones and/or royalty payments to Evotec based on the success of the program

Marksans Pharma updates on USFDA inspection at Verna, Goa manufacturing facility

Akums launches Bharosa campaign

The campaign marks an important milestone in its journey within the pharmaceutical manufacturing industry

USFDA grants ODD to NM5072 for treatment of Paroxysmal Nocturnal Hemoglobinuria

NM5072 is an anti-Properdin antibody that selectively blocks the alternative pathway while maintaining the integrity of the classical pathway required for fending off infections

AstraZeneca’s Imfinzi plus chemotherapy doubled overall survival rate for patients with advanced biliary tract cancer

Longest survival follow-up ever reported for immunotherapy treatment in this setting

Positive data for Roche multiple sclerosis injection

US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024

Suven Life Sciences to present phase-2 results on Samelisant at AAN 2024

Global Phase-3 study initiation expected in the second half of 2024